These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25111500)

  • 1. Neuromelanin magnetic resonance imaging reveals increased dopaminergic neuron activity in the substantia nigra of patients with schizophrenia.
    Watanabe Y; Tanaka H; Tsukabe A; Kunitomi Y; Nishizawa M; Hashimoto R; Yamamori H; Fujimoto M; Fukunaga M; Tomiyama N
    PLoS One; 2014; 9(8):e104619. PubMed ID: 25111500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus.
    Shibata E; Sasaki M; Tohyama K; Otsuka K; Endoh J; Terayama Y; Sakai A
    Biol Psychiatry; 2008 Sep; 64(5):401-6. PubMed ID: 18452894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.
    Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y
    Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of changes in the ventral tegmental area of patients with schizophrenia using neuromelanin-sensitive MRI.
    Yamashita F; Sasaki M; Fukumoto K; Otsuka K; Uwano I; Kameda H; Endoh J; Sakai A
    Neuroreport; 2016 Mar; 27(5):289-94. PubMed ID: 26901057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.
    Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA
    Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromelanin Magnetic Resonance Imaging of the Substantia Nigra in Huntington's Disease.
    Leitão R; Guerreiro C; Nunes RG; Gonçalves N; Galati G; Rosário M; Guedes LC; Ferreira JJ; Reimão S
    J Huntingtons Dis; 2020; 9(2):143-148. PubMed ID: 32065802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual discrimination among patients with depression and schizophrenia and healthy individuals using semiquantitative color-coded fast spin-echo T1-weighted magnetic resonance imaging.
    Sasaki M; Shibata E; Ohtsuka K; Endoh J; Kudo K; Narumi S; Sakai A
    Neuroradiology; 2010 Feb; 52(2):83-9. PubMed ID: 19756561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging.
    Ohtsuka C; Sasaki M; Konno K; Kato K; Takahashi J; Yamashita F; Terayama Y
    Parkinsonism Relat Disord; 2014 Jul; 20(7):755-60. PubMed ID: 24768616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies.
    Kitao S; Matsusue E; Fujii S; Miyoshi F; Kaminou T; Kato S; Ito H; Ogawa T
    Neuroradiology; 2013 Aug; 55(8):947-953. PubMed ID: 23673875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for Dopamine Abnormalities in the Substantia Nigra in Cocaine Addiction Revealed by Neuromelanin-Sensitive MRI.
    Cassidy CM; Carpenter KM; Konova AB; Cheung V; Grassetti A; Zecca L; Abi-Dargham A; Martinez D; Horga G
    Am J Psychiatry; 2020 Nov; 177(11):1038-1047. PubMed ID: 32854531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.
    Hatano T; Okuzumi A; Kamagata K; Daida K; Taniguchi D; Hori M; Yoshino H; Aoki S; Hattori N
    J Neural Transm (Vienna); 2017 Apr; 124(4):407-415. PubMed ID: 28160151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis.
    Ueno F; Iwata Y; Nakajima S; Caravaggio F; Rubio JM; Horga G; Cassidy CM; Torres-Carmona E; de Luca V; Tsugawa S; Honda S; Moriguchi S; Noda Y; Gerretsen P; Graff-Guerrero A
    Neurosci Biobehav Rev; 2022 Jan; 132():1205-1213. PubMed ID: 34718049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy.
    Miyoshi F; Ogawa T; Kitao SI; Kitayama M; Shinohara Y; Takasugi M; Fujii S; Kaminou T
    AJNR Am J Neuroradiol; 2013; 34(11):2113-8. PubMed ID: 23744697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normative data of dopaminergic neurotransmission functions in substantia nigra measured with MRI and PET: Neuromelanin, dopamine synthesis, dopamine transporters, and dopamine D
    Ito H; Kawaguchi H; Kodaka F; Takuwa H; Ikoma Y; Shimada H; Kimura Y; Seki C; Kubo H; Ishii S; Takano H; Suhara T
    Neuroimage; 2017 Sep; 158():12-17. PubMed ID: 28655632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
    Kashihara K; Shinya T; Higaki F
    J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.